The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials

Tislelizumab is an anti-programmed death-1 (PD-1) monoclonal antibody with a construction that enables it to have a higher affinity to its target. We aimed to evaluate tislelizumab ’s safety and efficacy for tr...

Source: BMC Pulmonary Medicine - December 8, 2023 Category: Respiratory Medicine Authors: Amin Daei Sorkhabi, Mahta ZareDini, Asra Fazlollahi, Aila Sarkesh, Amirreza Naseri, Seyed Ehsan Mousavi, Seyed Aria Nejadghaderi, Mark J M Sullman, Ali-Asghar Kolahi and Saeid Safiri Tags: Research Source Type: research